Jannsen's R&D Booster Shot
Executive Summary
J&J's most productive research house, Janssen Pharmaceutica, has always depended on its own in-house research programs, shunning biotech alliances. But even Janssen sees the handwriting on the wall: it can't continue to be productive at the required rate without help from smaller partners: thus its recent deals with Chiron, Gliatech, and Neurocrine,